Skip to main content

vistusertib

Generic: Vistusertib

vistusertib: 3 clinical trials tracked.

vistusertib evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about vistusertib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).

NCT02546661Registry updated 2026-10-01·Phase 1·AZN
Active, not recruiting

Primary endpoint: Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.

InterventionalRandomizedopen117 enrolledStarted 2016-12Completion 2026-1127 sites · Canada, France, Spain, United Kingdom…AstraZeneca

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

NCT02664935Registry updated 2026-04-28·Phase 2
Completed

Primary endpoint: Objective response (OR)

Interventionalopen423 enrolledStarted 2015-05Completion 2023-1125 sites · United KingdomUniversity of Birmingham

A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer

NCT01597388Registry updated 2026-02-24·Phase 1·AZN
Completed

Primary endpoint: Adverse Events

Interventionalopen99 enrolledStarted 2012-05Completion 2026-015 sites · United StatesAstraZeneca